Prospective observational study to investigate the predictive factors on the efficacy of molecular targeting therapy for unresectable advanced hepatocellular carcinoma.
Not Applicable
- Conditions
- hepatocellular carcinoma
- Registration Number
- JPRN-UMIN000010000
- Lead Sponsor
- Japanese Red Cross Liver Study Group
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 150
Inclusion Criteria
Not provided
Exclusion Criteria
Patients with Eastern Cooperative Oncology Group (ECOG) performance status of 3 or 4 and pretreatment Child-Pugh score of 8 or more.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The clinicopathological factors related to time to progression of unresectable advanced hepatocellular carcinoma.patients treated with sorafenib.
- Secondary Outcome Measures
Name Time Method The clinicopathological factors related to overall survival of unresectable advanced hepatocellular carcinoma patients treated with sorafenib. The clinicopathological factors to predict serious adverse effects caused by sorafenib.